Genmab A/S (GMAB) News Today $20.66 +0.16 (+0.78%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$20.51 -0.15 (-0.72%) As of 07:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GMAB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Completion of Share Buy-back ProgramJune 30 at 9:30 AM | globenewswire.comGenmab A/S (GMAB) Latest Stock News & Headlines - Yahoo FinanceJune 27, 2025 | finance.yahoo.comOppenheimer Asset Management Inc. Purchases 42,361 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)June 25, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume - Here's WhyJune 24, 2025 | marketbeat.comGenmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As OneJune 23, 2025 | seekingalpha.comTransactions in Connection with Share Buy-back ProgramJune 23, 2025 | globenewswire.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Acquired by QRG Capital Management Inc.June 20, 2025 | marketbeat.comGAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)June 19, 2025 | marketbeat.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseJune 17, 2025 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsJune 17, 2025 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 16, 2025 | globenewswire.comPark Avenue Securities LLC Takes Position in Genmab A/S (NASDAQ:GMAB)June 16, 2025 | marketbeat.comGenmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)June 15, 2025 | businesswire.comGenmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)June 15, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Wall Street ZenJune 14, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by AnalystsJune 13, 2025 | marketbeat.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJune 12, 2025 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 10, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Downgraded to Hold Rating by Wall Street ZenJune 6, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?June 3, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up - What's Next?June 3, 2025 | marketbeat.comGenmab advances with lower dose of Rina-S in endometrial cancer trialsJune 3, 2025 | investing.comWhy Genmab Stock Smashed It on MondayJune 2, 2025 | finance.yahoo.comGenmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOLâ„¢-01 TrialJune 2, 2025 | businesswire.comGenmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 TrialJune 2, 2025 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 2, 2025 | globenewswire.comLegacy Wealth Asset Management LLC Purchases 13,246 Shares of Genmab A/S (NASDAQ:GMAB)June 2, 2025 | marketbeat.com33,010 Shares in Genmab A/S (NASDAQ:GMAB) Bought by Mackenzie Financial CorpJune 2, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Acquired by Squarepoint Ops LLCMay 29, 2025 | marketbeat.comEmployees Retirement System of Texas Invests $1.65 Million in Genmab A/S (NASDAQ:GMAB)May 28, 2025 | marketbeat.comGenmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare ConferenceMay 27, 2025 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 26, 2025 | globenewswire.comGTS Securities LLC Acquires Shares of 74,356 Genmab A/S (NASDAQ:GMAB)May 26, 2025 | marketbeat.comBank of America Corp DE Has $9.91 Million Position in Genmab A/S (NASDAQ:GMAB)May 26, 2025 | marketbeat.comVoloridge Investment Management LLC Buys 561,767 Shares of Genmab A/S (NASDAQ:GMAB)May 25, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 88,146 Genmab A/S (NASDAQ:GMAB)May 24, 2025 | marketbeat.comQuantinno Capital Management LP Buys 66,128 Shares of Genmab A/S (NASDAQ:GMAB)May 24, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up - Should You Buy?May 23, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Bought by Two Sigma Advisers LPMay 23, 2025 | marketbeat.comTwo Sigma Investments LP Raises Stake in Genmab A/S (NASDAQ:GMAB)May 23, 2025 | marketbeat.comGenmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2025 | globenewswire.comGenmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2025 | businesswire.comOMERS ADMINISTRATION Corp Invests $378,000 in Genmab A/S (NASDAQ:GMAB)May 22, 2025 | marketbeat.comGenmab reports capital increase due to warrant exercisesMay 22, 2025 | uk.investing.comGenmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care ConferenceMay 21, 2025 | globenewswire.comGenmab AS ADR GMABMay 20, 2025 | morningstar.comMCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 20, 2025 | globenewswire.comTema Etfs LLC Acquires New Position in Genmab A/S (NASDAQ:GMAB)May 20, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 20, 2025 | marketbeat.comTransactions in Connection with Share Buy-back ProgramMay 19, 2025 | globenewswire.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼1.010.90▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼57▲GMAB Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenex News Today BeOne Medicines News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Dr. Reddy's Laboratories News Today Ascendis Pharma A/S News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.